STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 155516

TO: Emily M Le **Location: 3c35/3c18** **Art Unit: 1648** **Monday, June 06, 2005** **Case Serial Number: pctus9206688**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

155516

Jarrell, Noble

From: Le, Emily
Sent: Friday, June 03, 2005 11:29 PM
To: Jarrell, Noble
Subject: WO publication number

Noble,

I can't find the WO publication number for PCT/US92/06688 and PCT/US92/10378. Please assist by searching for the WO publication number of those applications. Thanks, Noble.

Emily Le
Office, Rem 3C35
Mailbox, Rem 3C18
Tel., 2-0903

Noble
Fin 6/6/05
other
STN
5pr
60rl

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 12:35:54 ON 06 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 6 Jun 2005  VOL 142 ISS 24
FILE LAST UPDATED: 5 Jun 2005  (20050605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l3 tot

L3   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2001:241687  HCAPLUS
DN   134:265129
ED   Entered STN:  05 Apr 2001
TI   Methods and compositions for the priming of specific cytotoxic
     T-lymphocyte response
IN   Sastry, Jagannadha K.; Arlinghaus, Ralph B.; Platsoucas, Chris D.
PA   Board of Regents, the University of Texas System, USA
SO   U.S., 24 pp., Cont.-in-part of U.S. 5,128,319.
     CODEN: USXXAM
DT   Patent
LA   English
IC   ICM  C12Q001-70
INCL 435005000
CC   15-1 (Immunochemistry)
FAN.CNT 4
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   US 6210873            B1    20010403    US 1991-800932           19911202
     US 5128319            A     19920707    US 1989-410727           19890920
     US 6265539            B1    20010724    US 1992-834923           19920213
     WO 9310816            A1    19930610    WO 1992-US10378          19921202 <--
          W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP,
             KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, UA
          RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
             BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG
     AU 9332339            A1    19930628    AU 1993-32339            19921202 <--
     AU 666160             B2    19960201
     JP 07502729           T2    19950323    JP 1992-510318           19921202 <--
     EP 671947             A1    19950920    EP 1993-900770           19921202 <--
     EP 671947             B1    20000308
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     EP 968721             A2    20000105    EP 1999-112007           19921202
     EP 968721             A3    20040204
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
     AT 190226             E     20000315    AT 1993-900770           19921202 <--
     ES 2145768            T3    20000716    ES 1993-900770           19921202
     PT 671947             T     20000731    PT 1993-900770           19921202
     GR 3033488            T3    20000929    GR 2000-401185           20000524 <--
```

	US 2002151678	A1	20021017	US 2001-911838	20010724
PRAI	US 1987-90646	B2	19870828		
	US 1989-410727	A2	19890920		
	US 1991-800932	A	19911202		
	US 1992-834923	A1	19920213		
	US 1992-945865	A	19920916		
	EP 1993-900770	A3	19921202		
	WO 1992-US10378	A	19921202	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6210873	ICM	C12Q001-70
	INCL	435005000
US 6210873	NCL	435/005.000; 424/009.200; 424/184.100; 424/204.100; 424/207.100; 424/208.100; 435/007.100; 435/007.240; 435/325.000; 435/974.000
	ECLA	C07K014/16; C07K014/16D; G01N033/50D2F2
US 5128319	NCL	424/188.100; 424/208.100; 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000
US 6265539	NCL	530/326.000; 530/327.000; 530/350.000
	ECLA	C07K014/16; C07K014/16D
EP 968721	ECLA	A61K039/12; C07K014/115; C07K014/16; C07K014/16D; G01N033/50D2F2; G01N033/50D2J4
US 2002151678	NCL	530/326.000; 530/327.000; 530/350.000; 530/300.000; 536/023.720; 435/005.000; 424/188.100
	ECLA	C07K014/16; C07K014/16D

AB The present invention discloses a novel method for the rapid screening of candidate cytotoxic T lymphocyte- (CTL-) inducing compds., such as peptides, by the in vivo priming of CTLs with synthetic peptides. The use of compds. so identified for the development of CTL vaccines for the treatment of various infectious disorders, including the treatment of viral diseases such as AIDS, herpes, influenza, and feline or bovine leukemia, is also disclosed, as is the use of this methodol. for the preparation of specifically primed CTLs.

ST vaccine viral infection cytotoxic T lymphocyte peptide

IT Histocompatibility antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MHC (major histocompatibility complex), class I; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT T cell (lymphocyte)
(activation; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT T cell (lymphocyte)
(cytotoxic; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp120env; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp41env; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Drug delivery systems
(injections, intradermal; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT AIDS (disease)
B cell (lymphocyte)
Bovine leukemia virus

Cytolysis
Feline leukemia virus
Herpesviridae
Human immunodeficiency virus
Immunization
Influenza virus
Lymph node
Vaccines
(methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Antibodies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Nucleoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT Infection
(viral; methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

IT 111364-20-6 114416-46-5 114991-28-5 135540-12-4 135540-13-5
135540-14-6 135540-15-7 135540-16-8 135540-17-9 135540-18-0
135540-19-1 135540-20-4 135540-21-5 135540-22-6 135540-23-7
135540-24-8 135540-25-9 135540-26-0 135540-27-1 135540-28-2
135572-08-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(methods and compns. for priming of specific cytotoxic T-lymphocyte response and use of candidate peptides for preparation of CTL vaccines)

RE.CNT 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aichele; J Exp Med 1990, V171, P1815 HCAPLUS
(2) Anderson, C; Nature 1991, V353, P287 MEDLINE
(3) Anon; EP 044710 1982 HCAPLUS
(4) Anon; WO 8500807 1985 HCAPLUS
(5) Anon; WO 8606414 1986 HCAPLUS
(6) Anon; EP 0267802 1988 HCAPLUS
(7) Anon; EP 0273716 1988 HCAPLUS
(8) Anon; EP 0284587 1988 HCAPLUS
(9) Anon; WO 8805051 1988 HCAPLUS
(10) Anon; WO 8903844 1989 HCAPLUS
(11) Anon; WO 8907112 1989 HCAPLUS
(12) Anon; WO 9000901 1990 HCAPLUS
(13) Anon; WO 9101996 1991 HCAPLUS
(14) Anon; WO 9104045 1991 HCAPLUS
(15) Anon; WO 9104051 1991 HCAPLUS
(16) Anon; WO 9109869 1991 HCAPLUS
(17) Anon; WO 9113910 1991 HCAPLUS
(18) Anon; WO 9221377 1992 HCAPLUS
(19) Anon; WO 9304697 1993 HCAPLUS
(20) Anon; WO 9315750 1993 HCAPLUS
(21) Anon; WO 9318055 1993 HCAPLUS
(22) Anon; WO 9321218 1993 HCAPLUS
(23) Anon; WO 9400488 1994 HCAPLUS
(24) Anon; Bio/Technology, In the News 1988, V6, P345
(25) Anon; C&EN 1987, V65, P24
(26) Anon; PCT Search Report 1993
(27) Arlinghaus; US 5128319 1992 HCAPLUS

(28) Aron; US 4474795 1984 HCAPLUS
(29) Arthur; J Virol 1989, V63(12), P5046 HCAPLUS
(30) Austin American-Statesman; No publication given 1987
(31) Barnes; Science 1987, V237, P128 MEDLINE
(32) Barnes; Science 1987, V236, P1423 MEDLINE
(33) Barnes; Science 1987, V236, P255 MEDLINE
(34) Barnes; Science, Research News 1988, V241(533-534), P242
(35) Berzofsky; US 5030449 1991 HCAPLUS
(36) Berzofsky; US 5081223 1992 HCAPLUS
(37) Berzofsky; US 5081226 1992 HCAPLUS
(38) Berzofsky; Aids Res Hum Retroviruses 1991, V7(2), P144
(39) Berzofsky; FASEB J 1991, V5, P2412 MEDLINE
(40) Berzofsky; Nature 1988, V334, P706 HCAPLUS
(41) Berzofsky; Science 1985, V229, P932 HCAPLUS
(42) Bevan; Nature, News and Views 1989, V342, P478 MEDLINE
(43) Bloom; Nature 1987, V327, P193 MEDLINE
(44) Buller; Nature 1987, V328, P77 MEDLINE
(45) Cease; Proc Natl Acad Sci USA 1987, V84, P4249 HCAPLUS
(46) Chanh; EMBO Journal 1986, V5, P3065 HCAPLUS
(47) Clark; The Experimental Foundations of Immunology 1980, P278 MEDLINE
(48) Cleric; Nature 1989, V339, P383
(49) Clerici; J Immunol 1991, V146(7), P2214 HCAPLUS
(50) Coates; Nature 1987, V326, P549 HCAPLUS
(51) Coates; Nature 1987, V326, P549 HCAPLUS
(52) Cohen; Science 1992, V257, P152 MEDLINE
(53) Dadaglio; J Immunol 1991, V147(7), P2302 HCAPLUS
(54) Deich; US 5108744 1992 HCAPLUS
(55) Delisi, C; Proc Natl Acad Sci USA 1985, V82, P7048 HCAPLUS
(56) Deres; Nature 1989, V342 HCAPLUS
(57) Deres; Nature 1989, V342, P561 HCAPLUS
(58) Devash; PNAS 1990, V87, P3445 HCAPLUS
(59) Earl; Science 1986, V234, P728 HCAPLUS
(60) Earl; Science 1986, V234, P728 HCAPLUS
(61) Ellis; Vaccines, Chapter 29 1988, P568 MEDLINE
(62) Emini; J Virol 1990, V64(8), P3674 HCAPLUS
(63) Essex; US 4725669 1988 HCAPLUS
(64) Freed; AIDS Res Human Retroviruses 1991, V7(10), P807 HCAPLUS
(65) Freed; J Virol 1991, V65(1), P190 HCAPLUS
(66) Gallo; Scientific America 1987, P47
(67) Gao; J Immunol 1991, V147(10), P3268 HCAPLUS
(68) Ghiara; Science 1994, V264, P82 HCAPLUS
(69) Goldstein; US 4983387 1991 HCAPLUS
(70) Gray; Gray's Anatomy, Bounty Books (NY) 1977, P623 HCAPLUS
(71) Hart; Proc Natl Acad Sci USA 1991, V88, P9448 HCAPLUS
(72) Haynes; US 5013548 1991 HCAPLUS
(73) Haynes; US 5019387 1991 HCAPLUS
(74) Homay; Science 1989, V244, P1357
(75) Hopp; Mol Immunol 1984, V21, P13 HCAPLUS
(76) Hosmalin; PNAS 1990, V87, P2344 HCAPLUS
(77) Houghten; WO 8402700 1985 HCAPLUS
(78) Howell; Science 1989, V246, P668 HCAPLUS
(79) Javaherian; PNAS 1989, V86, P6768 HCAPLUS
(80) Kaneshima; Proc Natl Acad Sci USA 1991, V88, P4523 MEDLINE
(81) Kast; PNAS 1991, V88, P2283 HCAPLUS
(82) Kast; PNAS 1991, V88, P2283 HCAPLUS
(83) Kemp; Peptides:Chemistry, Structure and Biology, Proceedings the Eleventh American Peptide Symposium 1989
(84) Kennedy; Science 1986, V231, P1555
(85) Kion, T; Science 1991, V253, P1138 HCAPLUS
(86) Kloetzer; WO 8805783 1989 HCAPLUS
(87) Koenig; PNAS 1988, V85, P8638 HCAPLUS
(88) Lagrain; J Virol 1986, V60, P1141
(89) Larosa; Science 1990, V249, P932 HCAPLUS
(90) Lasarte; Cellular Immunology 1992, V141, P211 HCAPLUS
(91) Livingstone; Ann Rev Immunol 1987, V5, P477 HCAPLUS
(92) Livingstone; Ann Rev Immunol 1987, V5, P477 HCAPLUS

Search done by Noble Jarrell

(93) Maddon; Cell 1986, V47, P333 HCAPLUS
(94) Maddon; PNAS 1987, V84, P9155 HCAPLUS
(95) Maddox, J; Nature 1991, V353, P297 MEDLINE
(96) Margalit; J Immunol 1987, V138(7), P2213 HCAPLUS
(97) McMichael; EP 346022 1990 HCAPLUS
(98) Milich; J Exp Med 1986, V164, P532 HCAPLUS
(99) Milich; J Exp Med 1986, V164, P532 HCAPLUS
(100) Milich; Science 1986, V234, P1563
(101) Miller; Nature-News and Views 1988, V332, P109 MEDLINE
(102) Mitsuya; Nature 1987, V325, P773 HCAPLUS
(103) Modrow; J Virol 1987, V61, P570 HCAPLUS
(104) Murakami; BBA 1991, V1079, P279 HCAPLUS
(105) Nara; PNAS 1987, V84, P3797 MEDLINE
(106) Nestor; US 4493795 1985 HCAPLUS
(107) Newmark; Nature 1987, V325, P290 MEDLINE
(108) Newmark; Nature 1987, V327, P458 MEDLINE
(109) Nixon; Nature 1988, V336, P484 HCAPLUS
(110) Norley; Immunobiol 1992, V184, P193 MEDLINE
(111) Palker; PNAS 1988, V85, P1932 HCAPLUS
(112) Papsidero; US 5185147 1993 HCAPLUS
(113) Patarroyo; Nature 1988, V332, P158 HCAPLUS
(114) Putney; US 5142025 1992 HCAPLUS
(115) Putney; Science 1886, V234, P1392
(116) Reiher; Proc Natl Acad Sci USA 1986, V83, P9188 HCAPLUS
(117) Renia; Proc Natl Acad Sci USA 1991, V88, P7963 HCAPLUS
(118) Robey; Proc Natl Acad Sci USA 1986, V83, P7023 HCAPLUS
(119) Rosen; US 4943628 1990 HCAPLUS
(120) Rusche; Proc Natl Acad Sci USA 1988, V85, P3198 HCAPLUS
(121) Salk; Nature 1987, V327, P473 MEDLINE
(122) Sastry; Curr Sci 1991, V5, P699 HCAPLUS
(123) Sastry; Current Science 1991, V5(6), P699 HCAPLUS
(124) Sastry; Hematologic Pathology 1990, V4(3), P157 MEDLINE
(125) Sastry; Virology 1992, V188, P502 HCAPLUS
(126) Schild; Eur J Immunol 1991, V21, P2649 HCAPLUS
(127) Schulz; Proc Natl Acad Sci USA 1991, V88, P991 HCAPLUS
(128) Scott; PNAS 1990, V87, P8597 HCAPLUS
(129) Sette; Molec Immunol V23(8), P807 HCAPLUS
(130) Shinnick; WO 8701118 1988 HCAPLUS
(131) Shinnick; Ann Rev Microbiol 1983, V37, P425 HCAPLUS
(132) Shinnick; Ann Rev Microbiol 1983, V37, P425 HCAPLUS
(133) Sternberg; FEBS Letters 1987, V218, P231 HCAPLUS
(134) Sternberg; FEBS Letts 1987, V218(2), P231 HCAPLUS
(135) Takahashi; J Exp Med 1989, V170, P2023 HCAPLUS
(136) Takahashi; J Exp Med 1990, V171, P571 HCAPLUS
(137) Takahashi; PNAS 1988, V85, P3105 HCAPLUS
(138) Takahashi; Science 1989, V246, P118 HCAPLUS
(139) Takahashi; Science 1992, V255, P333 HCAPLUS
(140) Takeda; Science 1988, V242, P580 MEDLINE
(141) Thornton; US 4818527 1989 HCAPLUS
(142) Wain-Hobson; Cell 1985, V40, P9 HCAPLUS
(143) Walker; Science 1986, V234, P1563 HCAPLUS
(144) Walker; Science 1988, V240, P64 HCAPLUS
(145) Watari; J Exp Med 1987, V165, P459 HCAPLUS
(146) White; Medical Virology, 3rd ed 1986, P283
(147) Zarling; Nature 1986, V323, P344 MEDLINE
(148) Zarling; Nature 1986, V323, P344 MEDLINE

L3 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:579173 HCAPLUS
DN 119:179173
ED Entered STN: 30 Oct 1993
TI Peptide compositions for eliciting cytotoxic T-lymphocyte responses against viruses, including HIV
IN Sastry, Jagannadha K.; Arlinghaus, Ralph B.; Platsoucas, Chris D.; Nehete, Pramod N.
PA University of Texas System, USA

SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K039-21
ICS A61K039-12; C12Q001-02
CC 15-2 (Immunochemistry)
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9310816	A1	19930610	WO 1992-US10378	19921202	<--
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, UA					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG					
	US 6210873	B1	20010403	US 1991-800932	19911202	
	AU 9332339	A1	19930628	AU 1993-32339	19921202	<--
	AU 666160	B2	19960201			
	JP 07502729	T2	19950323	JP 1992-510318	19921202	<--
	EP 671947	A1	19950920	EP 1993-900770	19921202	<--
	EP 671947	B1	20000308			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	AT 190226	E	20000315	AT 1993-900770	19921202	<--
	GR 3033488	T3	20000929	GR 2000-401185	20000524	<--
PRAI	US 1991-800932	A	19911202			
	US 1992-945865	A	19920916			
	US 1987-90646	B2	19870828			
	US 1989-410727	A2	19890920			
	WO 1992-US10378	A	19921202	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9310816	ICM	A61K039-21
	ICS	A61K039-12; C12Q001-02
US 6210873	NCL	435/005.000; 424/009.200; 424/184.100; 424/204.100; 424/207.100; 424/208.100; 435/007.100; 435/007.240; 435/325.000; 435/974.000
	ECLA	C07K014/16; C07K014/16D; G01N033/50D2F2

AB Compns. and methods are provided for the prevention and treatment of viral infections. The identification of distinct classes of peptides for use in both antiviral vaccines and therapeutic formulations is reported. Peptide formulations are disclosed which enhance the systemic distribution, activity, and longevity of antiviral cytotoxic T-cells (CTL) and/or which protect human cells from HIV infection. A method for the rapid screening of CTL-inducing compds., for use in CTL vaccines and in the preparation of specifically primed CTL, is also disclosed. Sequences and activity of a variety of HIV-derived synthetic peptides are reported, as is induction of HIV-specific T-cell responses in monkeys on immunization with a synthetic peptide cocktail.

ST peptide cytotoxic T cell enhancement; vaccine HIV peptide; antiviral peptide cytotoxic T cell

IT Gene, microbial
RL: BIOL (Biological study)
(NEF, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide or HIV infection-inhibiting peptide derived from product of, of HIV, for anti-HIV composition)

IT Peptides, biological studies
RL: BIOL (Biological study)
(antiviral, with cytotoxic T-cell epitope and helper T-cell-inducing epitope or HIV infection-inhibiting sequence)

IT Proteins, biological studies
RL: BIOL (Biological study)
(cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide derived from, of HIV or influenza virus or sendai virus, for anti-viral composition)

IT Antibodies

RL: BIOL (Biological study)
(cytotoxic T-cell-inducing peptides which also elicit response to, antiviral in relation to)

IT Molecular structure-biological activity relationship
Protein sequences
(of HIV infection-inhibiting peptides)

IT Vaccines
(peptides inducing cytotoxic T-cell response for)

IT Virus, animal
(Sendai, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide derived from protein of, for antiviral composition)

IT Lymphocyte
(T-cell, cytotoxic, peptide with epitope for induction of, for antiviral composition)

IT Lymphocyte
(T-cell, helper cell, peptide with epitope for induction of, for antiviral composition)

IT Sialoglycoproteins
RL: BIOL (Biological study)
(gp120env, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide or HIV infection-inhibiting peptide derived from, of HIV, for anti-HIV composition)

IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(gp160env, peptides derived from, antibody and T-cell response to, cytotoxic T-cell-inducing peptides for antiviral compns. in relation to)

IT Virus, animal
(human immunodeficiency, infection with, inhibition of, peptides for)

IT Virus, animal
(human immunodeficiency 1, gp120 V3 loop peptides effect on human cells infected with)

IT Virus, animal
(influenza, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide derived from protein of, for antiviral composition)

IT Microorganism
(pathogenic, protein associated with, cytotoxic T-cell response to, composition inducing, screening of)

IT Gene, microbial
RL: BIOL (Biological study)
(env, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide or HIV infection-inhibiting peptide derived from product of, of HIV, for anti-HIV composition)

IT Gene, microbial
RL: BIOL (Biological study)
(gag, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide or HIV infection-inhibiting peptide derived from product of, of HIV, for anti-HIV composition)

IT Gene, microbial
RL: BIOL (Biological study)
(pol, cytotoxic T-cell-inducing peptide or helper T-cell-inducing peptide or HIV infection-inhibiting peptide derived from product of, of HIV, for anti-HIV composition)

IT 135540-31-7D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-32-8D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-34-0D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-36-2D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-38-4D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-41-9D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-42-0D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-43-1D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-44-2D, Gp160 fragment analog (human immunodeficiency virus

synthetic), cysteine-linked multimers 135540-45-3D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135540-46-4D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135572-09-7D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 135572-10-0D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 149600-31-7D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 149600-32-8D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 149600-33-9D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 149600-34-0D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 149600-35-1D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers 149600-36-2D, Gp160 fragment analog (human immunodeficiency virus synthetic), cysteine-linked multimers
RL: BIOL (Biological study)
(amino acid sequence and antibody and T-cell response of, cytotoxic T-cell-inducing anti-HIV composition in relation to)

IT 149600-37-3D, Gp160 fragment analog (human immunodeficiency virus synthetic), fatty acid reaction products 149600-38-4D, Gp160 fragment analog (human immunodeficiency virus synthetic), fatty acid reaction products 149600-39-5D, Gp160 fragment analog (human immunodeficiency virus synthetic), fatty acid reaction products 150375-16-9D, Gp160 fragment analog (human immunodeficiency virus synthetic), fatty acid reaction products
RL: BIOL (Biological study)
(amino acid sequence and antibody response of, cytotoxic T-cell-inducing anti-HIV composition in relation to)

IT 115416-08-5, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain IIIb synthetic) 135540-12-4, Gp120 amino-terminal fragment (human immunodeficiency virus) 149600-28-2, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain IIIb synthetic) 149600-29-3, Gp120 V3 loop fragment (human immunodeficiency virus-1mn synthetic) 149600-30-6, Gp120 V3 loop fragment (human immunodeficiency virus-1rf synthetic)
RL: PRP (Properties)
(amino acid sequence of, as HIV infection-inhibiting peptide, cytotoxic T-cell-inducing antiviral peptide compns. in relation to)

IT 114991-28-5, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain IIIb synthetic) 124693-73-8, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain MN synthetic) 124693-74-9, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain SC synthetic) 125159-22-0, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain RF synthetic) 139502-07-1, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain Z321 synthetic) 139502-09-3, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain NY-5 synthetic) 139502-10-6, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain CDC4 synthetic) 139502-11-7, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain Z3 synthetic) 139502-12-8, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain MAL synthetic) 139502-13-9, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain Z6 synthetic) 139502-14-0, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain JY1 synthetic) 139502-15-1, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain ELI synthetic) 146522-97-6, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain MN (Y-F) synthetic) 149600-23-7, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain MN synthetic) 149600-24-8, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain WMJ-3 synthetic) 149600-25-9, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain RF synthetic) 149600-26-0, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain SF-2 synthetic) 149600-27-1, Gp120 V3 loop fragment (human immunodeficiency virus-1 strain MN (Y-L) synthetic)
RL: PRP (Properties)
(amino acid sequence of, cytotoxic T-cell-inducing antiviral peptides in relation to)

IT 135540-27-1

RL: BIOL (Biological study)
(as helper T-cell-inducing peptide, for anti-HIV composition with cytotoxic T-cell-inducing peptide)
IT 114416-46-5, Nucleoprotein fragment (influenza virus synthetic)
133531-91-6, Nucleoprotein fragment (sendai virus synthetic)
RL: BIOL (Biological study)
(for cytotoxic T-cell-inducing antiviral peptide composition)

L3 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:470351 HCAPLUS
DN 119:70351
ED Entered STN: 21 Aug 1993
TI Multiple antigen peptide systems (MAPS) for use as HIV vaccines
IN Tam, James P.; Profy, Albert T.
PA Repligen Corp., USA; Rockefeller University
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K039-385
ICS A61K039-21; A61K039-12; A61K047-48; C07K017-02; C07K007-02; C07K007-06; C07K007-08; C07K007-10
CC 15-2 (Immunochemistry)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9303766	A1	19930304	WO 1992-US6688	19920811 <--

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE
PRAI US 1991-744281 A 19910813
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9303766	ICM	A61K039-385
	ICS	A61K039-21; A61K039-12; A61K047-48; C07K017-02; C07K007-02; C07K007-06; C07K007-08; C07K007-10

AB A MAPS useful as a vaccine against human immunodeficiency virus (HIV) has a dendritic core covalently attached to (1) a peptide which has partial homol. to the V3 loop of protein gp120 of HIV-I-MN and includes the sequence IGPGR and preferably also (2) a T-cell epitope. Thus, a tetravalent MAPS containing amino acids 308-331 of gp120 and a tandem B-cell epitope (including a T-helper cell determinant) on a lysine core induced high antiserum titers in mice.
ST vaccine human immunodeficiency virus peptide; HIV peptide vaccine
IT Vaccines
(for human immunodeficiency virus, multiple antigen peptide system with dendritic lysine core as)
IT Peptides, biological studies
RL: BIOL (Biological study)
(vaccine for human immunodeficiency virus containing multiple, on dendritic lysine core)
IT Lymphocyte
(T-cell, antigen epitope of, on multiple antigen peptide system with dendritic lysine core as vaccine for human immunodeficiency virus)
IT Virus, animal
(human immunodeficiency, vaccine for, multiple antigen peptide system with dendritic lysine core as)
IT Virus, animal
(human immunodeficiency 1, vaccine for, multiple antigen peptide system with dendritic lysine core as)
IT 115416-08-5 122589-24-6 128910-44-1 131474-11-8 131474-12-9
131474-13-0 134649-39-1 135825-89-7 135825-91-1 144095-02-3
147666-68-0 147666-69-1 147666-70-4 147666-71-5 147688-02-6
147688-03-7 148857-13-0
RL: BIOL (Biological study)
(multiple antigen peptide system containing, as vaccine for human

```
      immunodeficiency virus)
IT   56-87-1, Lysine, biological studies
     RL: BIOL (Biological study)
        (multiple antigen peptide system with dendritic core containing, as vaccine
        for human immunodeficiency virus)


=> b wpix
FILE 'WPIX' ENTERED AT 12:36:12 ON 06 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED:          3 JUN 2005      <20050603/UP>
MOST RECENT DERWENT UPDATE:     200535        <200535/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
    PLEASE VISIT:
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
    http://thomsonderwent.com/coverage/latestupdates/           <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
    GUIDES, PLEASE VISIT:
    http://thomsonderwent.com/support/userguides/               <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
    DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
    FIRST VIEW - FILE WPIFV.
    FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv  <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
    PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
    FOR DETAILS. <<<

=> d iall l6 tot

L6   ANSWER 1 OF 2  WPIX  COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER:      1993-196739 [24]   WPIX
CROSS REFERENCE:       1989-099870 [13]; 1991-117325 [16]
DOC. NO. CPI:          C1993-087158
TITLE:                 Peptide composition for treating and preventing viral
                       infections - comprise CTL-inducing epitope and HIV
                       infection-inhibiting sequence or T helper cell-inducing
                       sequence.
DERWENT CLASS:         B04 C06 D16
INVENTOR(S):           ARLINGHAUS, R B; NEHETE, P N; PLATSOUCAS, C D; SASTRY, J
                       K
PATENT ASSIGNEE(S):    (TEXA) UNIV TEXAS SYSTEM; (TEXA) UNIV TEXAS
COUNTRY COUNT:         41
PATENT INFORMATION:

     PATENT NO       KIND DATE     WEEK    LA   PG MAIN IPC
     ------------------------------------------------------
     WO 9310816      A1 19930610 (199324)* EN  130 A61K039-21
        RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE
         W: AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW
            NL NO NZ PL PT RO RU SD SE UA
     AU 9332339      A  19930628 (199342)
     JP 07502729     W  19950323 (199520)          A61K039-00
     EP 671947       A1 19950920 (199542)  EN
         R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
     AU 666160       B  19960201 (199612)          A61K039-21
     EP 968721       A2 20000105 (200006)  EN      A61K039-21
         R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
```

EP 671947	B1 20000308 (200017)	EN	A61K039-21	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE				
DE 69230769	E 20000413 (200025)		A61K039-21	
ES 2145768	T3 20000716 (200039)		A61K039-21	
US 6210873	B1 20010403 (200120)		C12Q001-70	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE	
WO 9310816	A1	WO 1992-US10378	19921202	<--
AU 9332339	A	AU 1993-32339	19921202	
JP 07502729	W	WO 1992-US10378	19921202	<--
		JP 1993-510318	19921202	
EP 671947	A1	WO 1992-US10378	19921202	<--
		EP 1993-900770	19921202	
AU 666160	B	AU 1993-32339	19921202	
EP 968721	A2 Div ex	EP 1993-900770	19921202	
		EP 1999-112007	19921202	
EP 671947	B1	WO 1992-US10378	19921202	<--
		EP 1993-900770	19921202	
	Related to	EP 1999-112007	19921202	
DE 69230769	E	DE 1992-630769	19921202	
		WO 1992-US10378	19921202	<--
		EP 1993-900770	19921202	
ES 2145768	T3	EP 1993-900770	19921202	
US 6210873	B1 CIP of	US 1987-90646	19870828	
	CIP of	US 1989-410727	19890920	
		US 1991-800932	19911202	

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9332339	A	Based on	WO 9310816
JP 07502729	W	Based on	WO 9310816
EP 671947	A1	Based on	WO 9310816
AU 666160	B	Previous Publ.	AU 9332339
		Based on	WO 9310816
EP 968721	A2	Div ex	EP 671947
EP 671947	B1	Related to	EP 968721
		Based on	WO 9310816
DE 69230769	E	Based on	EP 671947
		Based on	WO 9310816
ES 2145768	T3	Based on	EP 671947
US 6210873	B1	CIP of	US 5128319

PRIORITY APPLN. INFO: US 1992-945865 19920916; US
1991-800932 19911202; US
1987-90646 19870828; US
1989-410727 19890920

REFERENCE PATENTS: 11Jnl.Ref; EP 433242; WO 8902277; WO 9000901; WO 9104045; WO 9104051

INT. PATENT CLASSIF.:
MAIN: A61K039-00; A61K039-21; C12Q001-70
SECONDARY: A61K038-00; A61K039-12; A61K039-385; C12Q001-02

BASIC ABSTRACT:

WO 9310816 A UPAB: 20021105

Compsn. comprises a first and second peptide, the first peptide comprising a cytotoxic T-lymphocyte (CTL)-inducing epitope and the second peptide comprising either a HIV infection-inhibiting sequence or a T helper cell-inducing epitope. The sequences of the peptides are derivative from e.g. HIV gp. 1Z0, an influenza virus protein or a Sendai virus protein.

Also claimed are: (B) a method for identifying a candidate substance capable of enhancing a CTL response comprising (a) administering to an animal both the candidate substance and an immunogen capable of inducing a

CTL response, (b) recovering CTLs from the animal and (c) determining whether the CTL response is enhanced by the presence of the candidate substance; (c) a method for enhancing the CTL response of an animal to a CTL-inducing immunogen comprising additionally administering to the animal a peptide bearing a T helper cell epitope; (D) a method of assaying a compsn. for its ability to induce a cytotoxic T cell response, comprising (a) immunising an animal with a single injection of the candidate compsn., pref. by intradermal immunisation, (b) recovering cytotoxic T cells from lymph nodes of the immunised animal and (e) determining whether the cytotoxic T cells have been activated by the compsn.; (E) a method for preparing a vaccine, comprising (a) identifying compsn. capable of specifically priming CTLs; and (b) admixing compsn. with diluent(s) or additive(s); (F) a method of preparing cytotoxic T cells specifically primed to a selected compsn., comprising (a) immunising an animal with a compsn. capable of priming cytotoxic T cells and (b) recovering cytotoxic T cells from draining lymph nodes of the immunised animal.

USE/ADVANTAGE - Enhance the systemic distribution, level of activity and longevity of virus-specific CTLs. Used to inhibit virus infection of cells, in assay protocols and as therapeutic agents for use in the treatment of viral infections e.g. AIDS, herpes, influenza and feline leukaemia. The CTL priming assays are used to identify components for use in the preparation of vaccines for the treatment and/or prevention of viral diseases or parasitic or bacterial infections.

Dwg.0/18

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB
MANUAL CODES: CPI: B02-V02; C02-V02; B04-B04A3; C04-B04A3; B04-C01; C04-C01; B11-C08E; C11-C08E; B12-G05; C12-G05; B12-K04A; C12-K04A; D05-H07; D05-H09

L6 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1993-093730 [11] WPIX
DOC. NO. CPI: C1993-041421
TITLE: New multiple antigen peptide(s) as HIV vaccines - include a dendritic core covalently bonded to peptide including the sequence IGPGR.
DERWENT CLASS: B04 D16
INVENTOR(S): PROFY, A T; TAM, J P
PATENT ASSIGNEE(S): (REPK) REPLIGEN CORP; (UYRQ) UNIV ROCKEFELLER
COUNTRY COUNT: 17
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9303766	A1	19930304	(199311)*	EN	35	A61K039-385

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
W: CA JP

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE	
WO 9303766	A1	WO 1992-US6688	19920811	<--

PRIORITY APPLN. INFO: US 1991-744281 19910813
REFERENCE PATENTS: 4.Jnl.Ref; EP 328403; EP 339695
INT. PATENT CLASSIF.:
MAIN: A61K039-385
SECONDARY: A61K039-12; A61K039-21; A61K047-48; C07K007-02; C07K007-06; C07K007-08; C07K007-10; C07K017-02

BASIC ABSTRACT:
WO 9303766 A UPAB: 19931122
A multiple antigen peptide system (MAPS) comprising a dendritic core covalently attached to a peptide, the peptide including the sequence IGPGR, the MAPS, when injected into a mammal, being capable of eliciting

an immune response.

Pref. the peptide includes the sequence KRKRIHIGPGRAFYTTK (I) (from the V3 loop region of gp120 env of HIV-I-MN). The MAPS pref. further comprises a covalently attached T cell epitope, pref. containing sequence QIINMWQEVGKAMYA (II). The dendritic core pref. includes lysine and is pref. tetravalent.

The dendritic core and the entire MAPS are pref. prepared by solid-phase peptide synthesis.

USE/ADVANTAGE - The MAPS containing peptides derived from the V3 loop of HIV-I-MN are capable of raising broadly neutralising antibodies which can block infection of cultured cells by a wide range of HIV-I strains. The T cell epitope can enhance the immune response. The MAPS can be used for generating antibodies and in vaccines for preventing HIV infection

Dwg.0/3

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB
MANUAL CODES: CPI: B02-V02; B04-C01; D05-C11; D05-H07

=> b home
FILE 'HOME' ENTERED AT 12:36:25 ON 06 JUN 2005

=> d his full

(FILE 'HOME' ENTERED AT 12:30:21 ON 06 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 12:30:27 ON 06 JUN 2005
L1 1 SEA ABB=ON PLU=ON WO1992-US6688#/AP,PRN
D SCA
D BIB
L2 2 SEA ABB=ON PLU=ON WO1992-US10378#/AP,PRN
L3 3 SEA ABB=ON PLU=ON (L1 OR L2)

FILE 'WPIX' ENTERED AT 12:35:08 ON 06 JUN 2005
L4 1 SEA ABB=ON PLU=ON WO1992-US6688#/AP,PRN
L5 1 SEA ABB=ON PLU=ON WO1992-US10378#/AP,PRN
L6 2 SEA ABB=ON PLU=ON (L4 OR L5)